Designing phase 0 cancer clinical trials

Anthony J. Murgo, Shivaani Kummar, Larry Rubinstein, Martin Gutierrez, Jerry Collins, Robert Kinders, Ralph E. Parchment, Uping Ji, Seth M. Steinberg, Sherry X.yang, Melinda Hollingshead, Alice Chen, Lee Helman, Robert Wiltrout, Joseph E.tomaszewski, James H. Doroshow

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

Phase 0 trials are designed primarily to evaluate the pharmacodynamic and/or pharmacokinetic properties of selected investigational agents before initiating more traditional phase I testing. One of the major objectives of phase 0 trials is to interrogate and refine a target or biomarker assay for drug effect in human samples implementing procedures developed and validated in preclinical models. Thus, close collaboration between laboratory scientists and clinical investigators is essential to the design and conduct of phase 0 trials. Given the relatively small number of patients and tissue samples, showing a significant drug effect in phase 0 trials requires precise and reproducible assay procedures and innovative statistical methodology. Furthermore, phase 0 trials involving limited exposure of a study agent administered at low doses and/or for a short period allow them to be initiated under the Food and Drug Administration exploratory investigational new drug guidance with less preclinical toxicity data than usually required for traditional first-in-human studies. Because of the very limited drug exposure, phase 0 trials offer no chance of therapeutic benefit, which can impede patient enrollment, particularly if invasive tumor biopsies are required. The challenges to accrual are not insurmountable, however, and well-designed and executed phase 0 trials are feasible and have great potential for improving the efficiency and success of subsequent trials, particularly those evaluating molecularly targeted agents.

Original languageEnglish (US)
Pages (from-to)3675-3682
Number of pages8
JournalClinical Cancer Research
Volume14
Issue number12
DOIs
StatePublished - Jun 15 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Designing phase 0 cancer clinical trials'. Together they form a unique fingerprint.

Cite this